Zusammenfassung
Aufgrund neuer Studiendaten mit Immuncheckpoint-Inhibitoren (ICI) gewinnt der Nachweis einer hochgradigen Mikrosatelliteninstabilität (MSI-H) bzw. der zugrunde liegenden Mismatch-Repair-Protein-Defizienz (dMMR) nun auch zur Prädiktion von Therapieansprechen zunehmend an Bedeutung. Aktuell wurde von der Europäischen Medizinischen Agentur (EMA) erstmals ein PD-1-ICI (Pembrolizumab) für die Erstlinientherapie des fortgeschrittenen (Stadium IV) dMMR/MSI‑H kolorektalen Karzinoms (KRK) zugelassen. Weitere Indikationen, wie z. B. für das metastastasierte dMMR/MSI-H-Endometriumkarzinom (EK) in der Zweitlinientherapie (Dostarlimab) sind bereits gefolgt, andere werden noch im laufenden Jahr 2021 erwartet. Dies erfordert eine Neubewertung der Frage nach der optimalen Testung in der Routinediagnostik. Auf Basis einer Abwägung von Stärken und Schwächen der in der Breite zur Verfügung stehenden Methoden (Immunhistochemie und PCR) wird ein Testalgorithmus vorgeschlagen, der qualitätsgesichert eine zuverlässige und kosteneffektive dMMR/MSI-H-Testung erlaubt. Für das KRK und EK ist damit analog internationaler Empfehlungen (NICE, NCCN) eine Testung bereits bei der Primärdiagnose möglich. Somit wird der Kliniker von vornherein in die Lage versetzt, neben den prädiktiven auch die prognostischen und prädispositionsbedingten Implikationen eines solchen Tests bei der Beratung von Patienten und Erarbeitung von Therapieempfehlungen zu berücksichtigen. Als Grundlage der Qualitätssicherung wird die Teilnahme an Ringversuchen und eine fortlaufende Ergebnisdokumentation (z. B. QuIP-Monitor) empfohlen.
Abstract
Based on new trial data regarding immune checkpoint inhibitors (ICIs), the detection of high-grade microsatellite instability (MSI-H) or underlying deficient mismatch repair protein (dMMR) is now becoming increasingly important for predicting treatment response. For the first time, a PD‑1 ICI (pembrolizumab) has been approved by the European Medicines Agency (EMA) for first-line treatment of advanced (stage IV) dMMR/MSI‑H colorectal cancer (CRC). Further indications, such as dMMR/MSI‑H endometrial carcinoma (EC), have already succeeded (Dostarlimab, 2nd line treatment) and others are expected to follow before the end of 2021. The question of optimal testing in routine diagnostics should therefore be re-evaluated. Based on a consideration of the strengths and weaknesses of the widely available methods (immunohistochemistry and PCR), a test algorithm is proposed that allows quality assured, reliable, and cost-effective dMMR/MSI‑H testing. For CRC and EC, testing is therefore already possible at the primary diagnosis stage, in line with international recommendations (NICE, NCCN). The clinician is therefore enabled from the outset to consider not only the predictive but also the prognostic and predispositional implications of such a test when counseling patients and formulating treatment recommendations. As a basis for quality assurance, participation in interlaboratory comparisons and continuous documentation of results (e.g., QuIP Monitor) are strongly recommended.
Literatur
André T, Shiu KK, Kim TW et al (2020) Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 383:2207–2218
AWMF (2018) S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom (AWMF-Registernummer: 032/034-OL)
AWMF (2019) S3-Leitlinie Kolorektales Karzinom (AWMF-Registernummer: 021/007OL)
Bass BP, Engel KB, Greytak SR, Moore HM (2014) A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen? Arch Pathol Lab Med 138(11):1520–1530
Bläker H, Haupt S, Morak M et al (2020) Age-dependent performance of BRAF mutation testing in Lynch syndrome diagnostics. Int J Cancer 147:2801–2810
Britton H, Huang L, Lum A et al (2019) Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecol Oncol 153:487–495
Buhard O, Suraweera N, Lectard A et al (2004) Quasimonomorphic mononucleotide repeats for high-level microsatellite instability analysis. Dis Markers 20:251–257
Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–337
Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202–209
Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD et al (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67–73
Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB et al (2013) The cancer genome atlas pan-cancer analysis project. Nat Genet 45:1113–1120
Carethers JM (2017) Microsatellite instability pathway and EMAST in colorectal cancer. Curr Colorectal Cancer Rep 13:73–80
Casey L, Singh N (2021) POLE, MMR, and MSI testing in endometrial cancer: proceedings of the ISGyP companion society session at the USCAP 2020 annual meeting. Int J Gynecol Pathol 40(1):5–16
Chen W, Frankel WL (2019) A practical guide to biomarkers for the evaluation of colorectal cancer. Mod Pathol 32:S1–S15
Cho KR, Cooper K, Croce S et al (2019) International society of gynecological pathologists (ISGyP) endometrial cancer project: guidelines from the special techniques and ancillary studies group. Int J Gynecol Pathol 38(1):S114–S122
Darvin P, Toor SM, Sasidharan Nair V, Elkord E (2018) Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 50:1–11
Devaraj B et al (2010) Relationship of EMAST and microsatellite instability among patients with rectal cancer. J Gastrointest Surg. https://doi.org/10.1007/s11605-010-1340-6
Dietmaier W, Büttner R, Rüschoff J (2019) Mikrosatelliteninstabilität: Aktueller Überblick über Methoden und Anwendungen. Pathologe 40(3):313–327
Dominguez-Valentin M et al (2020) Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants. Genet Med 22(1):15–25
Engel C, Forberg J, Holinski-Feder E et al (2006) Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. Int J Cancer 118:115–122
Green AK, Feinberg J, Makker V (2020) A review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Educ Book 40:1–7
Hayashi H, Nakagawa K (2020) Combination therapy with PD‑1 or PD-L1 inhibitors for cancer. Int J Clin Oncol 25(5):818–830
Horn LC, Emons G, Aretz S et al (2019) S3-Leitlinie Diagnostik und Therapie des Endometriumkarzinoms: Anforderungen an die Pathologie. Pathologe 40:21–35
https://www.clincaltrials.gov. Zugegriffen: 03.05.2021
Iivanainen S, Koivunen JP (2020) Possibilities of improving the clinical value of immune checkpoint inhibitor therapies in cancer care by optimizing patient selection. Int J Mol Sci 21:556
Jöhrens K, Dietmaier W, Utpatel K et al (2021) Qualitätssicherung in der MMRD und MSI Diagnostik. Pathologe, im Druck
Joost P et al (2014) Heterogenous mismatch-repair status in colorectal cancer. Diagn Pathol 9:126
Kim J, Park WY, Kim NKD et al (2017) Good laboratory standards for clinical next-generation sequencing cancer panel tests. J Pathol Transl Med 51:191–204
Kloth M, Ruesseler V, Engel C et al (2016) Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. Gut 65:1296–1305
Latham A, Srinivasan P, Kemel Y et al (2019) Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J Clin Oncol 37:286–295
Le DT, Durham JN, Smith KN et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD‑1 blockade. Science 357:409–413
Le DT, Kim TW, Van Cutsem E et al (2020) Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: keynote-164. J Clin Oncol 38:11–19
Le DT, Uram JN, Wang H et al (2015) PD‑1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520
Luchini C, Bibeau F, Ligtenberg MJL et al (2019) ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol 30:1232–1243
Marabelle A, Le DT, Ascierto PA et al (2020) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II keynote-158 study. J Clin Oncol 38:1–10
Mills AM, Liou S, Ford JM et al (2014) Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol 38:1501–1509
Mojtahed A, Schrijver I, Ford JM et al (2011) A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas. Mod Pathol 24:1004–1014
National Institute for Health and Care Excellence (NICE) (2021) NICE guidance on molecular testing strategies for Lynch syndrome in people with colorectal cancer. https://www.bsg.org.uk/clinical-resource/nice-guidance-on-molecular-testing-strategies-for-lynch-syndrome-in-people-with-colorectal-cancer/#:~:text=NICE%20recommends%20that%20microsatellite%20instability,the%20presence%20of%20Lynch%20Syndrome.Andhttps://www.nice.org.uk/guidance/dg42/chapter/3-Evidence. Zugegriffen: 21. Jan. 2021
NCCN (2021) https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Zugegriffen: 22. Jan. 2021
Niu BT, Hammond RFL, Leen SLS, Gilks CB, Singh N (2019) Two versus four immunostains for Lynch syndrome screening in endometrial carcinoma. Histopathology 75:442–445
Oaknin A, Gilbert L, Tinker AV et al (2020) LBA36—safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): results from garnet. Ann Oncol 31(4):S1142–S1215. https://doi.org/10.1016/annonc/annonc325
Overman MJ, Lonardi S, Wong KYM et al (2018) Durable clinical benefit with nivolumab plus Ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36:773–779
Pearlman R, Markow M, Knight D et al (2018) Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency. Mod Pathol 31:1891–1900
Peltomäki P (2016) Update on Lynch syndrome genomics. Fam Cancer 15:385–393
Ryan NAJ, McMahon R, Tobi S et al (2020) The proportion of endometrial tumours associated with lynch syndrome (petals): a prospective cross-sectional study. PLoS Med 17:e1003263
Shia J, Tang LH, Vakiani E et al (2009) Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol 33:1639–1645
Siemanowski J, Schömig-Markiefka B, Buhl T et al (2021) Managing difficulties of microsatellite instability testing in endometrial cancer-limitations and advantages of four different PCR based approaches. Cancers 13(6):1268. https://doi.org/10.3390/cancers13061268
Sohn BH et al (2017) Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res 23:4441–4449
Soslow RA, Tornos C, Park KJ et al (2019) Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the international society of gynecological pathologists. Int J Gynecol Pathol 38(1):S64–S74
Stelloo E, Jansen AML, Osse EM et al (2017) Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Ann Oncol 28:96–102
Talhouk A, McConechy MK, Leung S et al (2017) Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 123:802–813
Xicola RM, Llor X, Pons E et al (2007) Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst 99:244–252
Yang G, Zheng R‑Y, Jin Z‑S (2019) Correlations between microsatellite instability and the biological behaviour of tumors. J Cancer Res Clin Oncol 145:2891–2899
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
S. Merkelbach-Bruse: Honorar für Vorträge und Advisory Boards von AstraZeneca, Roche, Novartis, GSK, MSD, Targos, Molecular Health und Merck. R. Büttner: Honorar für Vorträge und Advisory Boards von AbbVie, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Illumina, Lilly, MSD, Novartis, Qiagen, Pfizer und Roche. Mitgründer und Scientific Advisor von Targos Mol. Path. Gmbh. A. Hartmann: Honorar für Vorträge und Advisory Boards von Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Illumina, Ipsen, Janssen, MSD, Nanostring, Novartis, Qiagen, QUIP GmbH, Roche und 3DHistotech. L.-C. Horn: Honorar für Vorträge und Advisory Boards von AstraZeneca, Roche, Dako, Novartis, Exact Sciences und GSK. D. Mayr: Honorar für Vorträge und Advisory Boards von AstraZeneca, MSD, Roche, Novartis und BMS. R. Knüchel: Honorar für Vorträge und Advisory Board von MSD. J. Rüschoff: Honorar für Vorträge und Advisory Boards von MSD/Merck, GSK, BMS, AstraZeneca, Roche, Exact Sciences und QuIP GmbH. Mitgründer und medizin. Leiter von Targos Mol. Path. Gmbh. H.-U. Schildhaus: Honorar für Vorträge und Advisory Boards von MSD, BMS, Pfizer, Novartis Oncology, Roche Pharma und Molecular Health. Angestellter von Targos Mol. Path. Gmbh. W. Weichert: Honorar für Vorträge und Advisory Boards von Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Bayer, Amgen, Astellas, Illumina, Siemens, Agilent, GSK, ADC und Molecular Health. M. Tiemann: Honorar für Vorträge und Advisory Boards von BMS und MSD. G. Baretton, M. Dietel, K. Jöhrens, H. Bläker, W. Dietmaier, T. Kirchner, P. Schirmacher und K. Tiemann geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
W. Roth, Mainz
Rights and permissions
About this article
Cite this article
Rüschoff, J., Baretton, G., Bläker, H. et al. MSI-Testung. Pathologe 42, 414–423 (2021). https://doi.org/10.1007/s00292-021-00944-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00292-021-00944-7
Schlüsselwörter
- DNA-Mismatch-Reparatur
- Endometriumkarzinome
- Immuncheckpoint-Inhibitoren
- Mikrosatelliteninstabilität
- Prognose
- Endometriumkarzinome